Elsevier
Elsevier,
Neuropharmacology, Volume 259, 15 November 2024
This review explores using nanotechnology to enhance the delivery of neuroprotective phytochemicals from medicinal plants for Alzheimer's disease (AD), addressing issues of bioavailability, solubility, and blood-brain barrier penetration, and highlights the potential of nanocarriers to revolutionize neuroprotective drug delivery and improve patient outcomes.
Elsevier,
Brain Research, Volume 1843, 15 November 2024
This study developed a novel mouse model with tamoxifen-inducible knockout of the Gnpat gene, enabling late-onset plasmalogen deficiency to investigate its role in Alzheimer's disease. The model exhibited significant plasmalogen reduction and associated behavioral and nerve function changes, providing a valuable tool for future research on plasmalogen involvement in neurodegeneration and potential therapies.
Elsevier,
Journal of Ethnopharmacology, Volume 333, 28 October 2024
This review investigates the connection between Type 2 Diabetes Mellitus and Alzheimer's disease, focusing on common mechanisms and the potential of traditional Indian herbs to manage both conditions. It also addresses the challenges and innovative strategies in delivering herbal formulations.
Elsevier,
Brain Research, Volume 1841, 15 October 2024
This study found that female 5XFAD mice exhibit early impairments in prefrontal-dependent cognitive functions and increased activity of prefrontal PV neurons, unlike their male counterparts. These findings suggest a potential mechanism for the higher risk of Alzheimer's disease in women, highlighting sex-specific early deregulation in the prefrontal cortex.
Elsevier,
Pharmacological Research, Volume 208, October 2024
The study explores the use of a novel gene delivery system, AAV-aMTD-Parkin, to enhance motor and cognitive functions in animal models of Parkinson’s and Alzheimer’s diseases. This system improves the delivery efficiency of therapeutic proteins, potentially offering a new treatment approach for these neurodegenerative disorders.
Elsevier,
Pharmacological Research - Modern Chinese Medicine, Volume 12, September 2024
The study investigates the neuroprotective effects of hordenine against AlCl3-induced Alzheimer’s disease in rats. Results show that hordenine improves memory and cognitive functions, suggesting its potential to reverse oxidative stress and neuroinflammation associated with Alzheimer’s
Elsevier,
Journal of Neuroscience Methods, Volume 409, September 2024
Despite significant investment, effective treatments for Alzheimer's disease (AD) have been elusive, necessitating improved quality and reproducibility of foundational laboratory evidence; to address this, AD-SOLES, an integrated workflow of automated tools and a publicly accessible interactive dashboard, has been developed to collect, curate, and visualize in vivo experimental evidence, enhancing evidence synthesis, tracking reporting quality, and aiding researchers in locating relevant data.
Elsevier,
Brain Research, Volume 1838, 1 September 2024
The study demonstrates that the peptide PHDP5, which inhibits dynamin-MT interaction, can rescue impaired endocytosis and synaptic transmission caused by tau in presynaptic terminals. When administered intranasally to Alzheimer's disease (AD) model mice, PHDP5 significantly improved learning and memory, suggesting its potential as a candidate for human AD therapy.
Elsevier,
Acta Pharmaceutica Sinica B, Volume 14, July 2024
The study discusses the latest developments in Alzheimer’s disease treatment, with a focus on monoclonal antibodies and aptamers. It covers the current state of therapies, recent drug approvals, and future perspectives on immunotherapeutic strategies.
Elsevier,
Neuropharmacology, Volume 252, 1 July 2024
Every year, 10 million people develop dementia, most commonly Alzheimer's disease (AD), and despite limited therapies and no prevention for cognitive decline, this review offers a neuroimmunological perspective on AD progression, focusing on the role of the NLRP3 inflammasome, its brain triggers, and the potential impact of various NLRP3 inhibitors currently under investigation in preclinical and clinical trials.
Elsevier,
Neuroscience Research, Volume 204, July 2024
This study found that Alzheimer’s disease neuropathological change (ADNC) is associated with gene expression changes that may impair cholesterol biosynthesis in neurones but not astrocytes, whilst levels of cortical cholesterol show a weak relationship to dementia status.
Elsevier,
Brain Research Bulletin, Volume 212, 15 June 2024
This study reveals that Dl-3-n-butylphthalide (NBP) improves learning deficits and reduces Aβ plaque deposition in Alzheimer's disease (AD) transgenic mice by enhancing microglial activation and phagocytosis of Aβ plaques. The therapeutic effects of NBP are linked to the AGE-RAGE signaling pathway, demonstrating its potential in alleviating cognitive impairment and neuroinflammation in AD.
Elsevier,
Molecular and Cellular Neuroscience, Volume 129, June 2024
Neurological disorders affect approximately one billion people worldwide, with significant disability and mortality impacts, and this review explores how Heparan sulfate proteoglycans (HSPGs) promote Tau fibril formation and tangles in Alzheimer's disease, and the potential role of tunnelling nanotubes (TNTs) in the intercellular transport of Tau and Amyloid β proteins, suggesting that HSPGs may influence TNT formation in neurodegenerative conditions.
Elsevier,
Journal of Neuroscience Methods, Volume 406, June 2024
This study presents an optimized method for isolating specific neuronal and glial cell populations and extracellular vesicles (EVs) from postmortem Alzheimer's disease (AD) cortical samples, demonstrating the feasibility of using a single cryopreserved brain sample to obtain RNA-seq and protein-level data, thereby enhancing understanding of neuron/glial interactions and disease progression.
Elsevier,
Neurochemistry International, Volume 176, June 2024
This study finds that impaired cellular immune dysfunction in AD patients was significantly correlated with abnormal MRS, and neuroimmune dysfunction may contribute to the pathogenesis of AD and alter the metabolism of neurotransmitters such as aspartic acid and MI in the brains of AD patients.
Elsevier,
Mechanisms of Ageing and Development, Volume 219, June 2024
This study identified key biochemical pathways and protein changes in the Alzheimer's disease (AD) human hippocampus, revealing increased expression of proteins VGF, GFAP, HSPB1, and APP, with UBC being most centrally involved, and highlighted the roles of four hub proteins (CD44, APP, ITGB2, APOE) linked to amyloid plaques and two (RPL24, RPS23) to neurofibrillary tangles, along with the impact of modified proteins on immune activation and synaptic disruption, uncovering potential therapeutic targets involving specific proteins, microRNAs, and transcription factors.
Elsevier,
Brain Research, Volume 1832, June 2024
Recent research on Alzheimer's disease (AD) suggests that microglia, immune cells in the brain, may play a beneficial role in early disease stages but become harmful in later stages due to various spatial, temporal, and transcriptional factors. Understanding the phenotypic heterogeneity and multiple states of microglia could lead to advancements in personalized medicine and improved treatment outcomes for AD patients.
Elsevier,
IBRO Neuroscience Reports, Volume 16, June 2024
This article summarizes current biomarkers, available treatments, and future therapeutic approaches for Alzheimer's disease, discussing drug targets like Amyloid β, Tau Protein, and various other mechanisms. Additionally, it highlights the historical use of Estradiol, outcomes of trials with antioxidants and omega-3 fatty acids, and ongoing clinical trials, providing a comprehensive overview of the evolving landscape in AD research and treatment.
Elsevier,
Neuroscience, Volume 546, 14 May 2024
This study investigated VGLUT1 and VGLUT2 expression in the medial temporal lobe and superior temporal gyrus in Alzheimer's disease (AD). The findings reveal region-specific vulnerabilities, with significantly lower VGLUT1 in the dentate gyrus and VGLUT2 in the subiculum and superior temporal gyrus, suggesting potential therapeutic targets that require further exploration.
Elsevier,
Pharmacological Research, Volume 203, May 2024
This article explores the link between alcohol consumption and Alzheimer’s disease (AD), focusing on how serotonergic dysfunction may mediate this relationship. It highlights the roles of neuroinflammation and proteostasis in this process
Elsevier,
Journal of Ginseng Research, Volume 48, May 2024
This review describes recent clinical contributors to ginseng components in clinical tests and introduces emerging evidence that ginseng components could be novel candidates for cognitive improvement in older individuals, as ginseng components improve SMI cognition and exhibits add-on effects when co-administered with early AD dementia drugs. The mechanism behind the beneficial effects of ginseng components and how it improves cognition are presented.
Elsevier,
Neuroscience, Volume 544, 19 April 2024
This study demonstrates that electroacupuncture (EA) improves learning and memory in the 5xFAD mouse model of Alzheimer's disease, likely by enhancing functional connectivity between the hippocampus and neocortex and reducing amyloid-β protein expression and deposition. These findings suggest that EA may positively impact resting-state brain activity and connectivity, contributing to cognitive and motor function improvements in AD.
Elsevier,
Brain Research, Volume 1829, 15 April 2024
Despite diagnostic challenges in differentiating lvPPA and nfvPPA, particularly in advanced cases, this study reveals divergent clinical courses and highlights the importance of assessing emotion processing capacity in dementia diagnosis and monitoring. Utilizing spatiotemporal LME modelling, the research provides valuable insights into the dynamic changes in brain atrophy and behavior, underscoring the need for ongoing evaluation of clinical requirements for patients and families over the disease course.
Elsevier,
Frontiers in Neuroendocrinology, Volume 73, April 2024
This review discusses the multifaceted physiological functions of cholecystokinin (CCK), its potential neuroprotective effects in Alzheimer’s and Parkinson’s diseases, and its therapeutic implications, including its impact on memory, neurotransmitters, and neuroprotection mechanisms.
Elsevier,
Mechanisms of Ageing and Development, Volume 217, February 2024
This paper conducts a scoping review of research on the involvement of the glymphatic system in Alzheimer's disease-related sleep disturbances, finding that sleep disturbances impact protein aggregation and toxicity, glymphatic sequelae in sleep-disordered breathing, circadian dysregulation, and potential interventions, thus providing insight into the role of sleep disturbances in AD pathogenesis through glymphatic disruption.
Elsevier,
Neurobiology of Disease, Volume 190, January 2024
In Alzheimer's disease research, cerebrospinal fluid (CSF) biomarkers Amyloid beta (Aβ), Tau, and pTau are well-validated, and this study demonstrates that a Z-score based harmonization approach can effectively standardize CSF and amyloid imaging data across multiple cohorts, providing consistent biomarker cut-offs and comparable GWAS results to traditional methods, without introducing spurious findings.
Elsevier,
Experimental Gerontology, Volume 184, December 2023
This article reviews recent research on the pathogenesis of Alzheimer's disease, emphasizing the role of the gut-brain axis and examining clinical and preclinical studies on fermented foods, which have shown promising effects on amyloid-β metabolism, inflammation, and cognitive impairment, suggesting potential for new therapeutic and preventive measures for Alzheimer's disease.
Elsevier,
Experimental Gerontology, Volume 183, November 2023
This study finds that pine nut peptide-zinc chelate improves Alzheimer's Disease (AD) in various ways which include (1) improving learning, memory, brain health, and gut balance in mice, and (2) treating cholinergic system changes, boosting cerebral antioxidants, and altering gut microbiota. Pine nut peptide-zinc chelate holds potential for AD therapy, requiring deeper mechanistic investigation.
Elsevier,
Translational Research in Anatomy, Volume 33, November 2023
The “contour smoothing” fractal analysis method can effectively examine cerebral hemispheres to detect and quantify age-related atrophic changes associated with normal or pathological aging. This method holds promise for clinical application in diagnosing neurodegenerative disorders, such as Alzheimer’s disease.
Elsevier,
European Journal of Radiology, Volume 165, August 2023
This review is to provide a comprehensive overview of recent developments in deep learning methodologies applied to brain MRI images for the classification of various stages of Alzheimer's disease, with a particular emphasis on early diagnosis. Furthermore, this review underscores the limitations of current research, discussing potential challenges and future research directions in this dynamic field.
Elsevier,
Journal of Pharmaceutical Analysis, Volume 13, July 2023
The study reveals that damage to the blood-brain barrier increases the proportion of microglia, a type of brain cell, which contributes to the progression of aging and Alzheimer's disease. It also identifies ten different functional types of microglia and underscores the significance of certain signalling pathways in communication between cells.
Elsevier,
Pharmacological Research - Modern Chinese Medicine, Volume 7, June 2023
This article explores the potential of Traditional Chinese Medicine (TCM) as a treatment for Alzheimer's disease, highlighting the holistic approach of TCM and its promising results in improving cognitive function in Alzheimer's patients. It emphasizes the need for further rigorous clinical trials to validate these findings.
Elsevier,
Neurochemistry International, Volume 165, May 2023
This review discusses the critical role of oxidative stress in the pathogenesis of neurological disorders such as stroke and Alzheimer's disease (AD), detailing the mechanisms of reactive oxygen species (ROS) generation in the brain and exploring the potential of antioxidant therapies as therapeutic targets.
Elsevier,
Mechanisms of Ageing and Development, Volume 211, April 2023
Growing evidence suggests that the gut microbiome plays a crucial role in Alzheimer's disease (AD) pathogenesis through the microbiota-gut-brain axis, with alterations in gut microbiome composition linked to increased intestinal permeability, blood-brain barrier impairment, and neuroinflammation, and that gut microbiome modulation may alleviate AD symptoms, serve as a preventive measure, and also address comorbidities like Type 2 Diabetes Mellitus (T2DM), with future research directions including fecal microbiota transplantation (FMT) and precision medicine.
Elsevier,
Frontiers in Neuroendocrinology, Volume 69, April 2023
This review discusses the link between isolation, loneliness, and Alzheimer's Disease, and underscores the necessity of understanding and addressing these risk factors to develop successful prevention and treatment approaches.
Elsevier,
Mechanisms of Ageing and Development, Volume 211, April 2023
This paper applies stochastic process models (SPM) to study Alzheimer's disease (AD) using data on AD onset and longitudinal body mass index (BMI) trajectories, revealing that APOE e4 carriers are less resilient to deviations in BMI, with age-related declines in adaptive response and differences in allostatic load accumulation, thereby providing new insights into the connections between age, genetic factors, and risk factors in AD development and aging.
Elsevier,
Journal of Ginseng Research, Volume 47, March 2023
Our results suggested that the therapeutic effects of NFP on AD were associated with synaptic- and mitochondrial-related pathways, and they provided targets for further rigorous studies on precise understanding of the molecular mechanism of NFP.
Elsevier,
Experimental Neurology, Volume 360, February 2023
This review discusses the role of the endocannabinoid system in pain management, particularly in the context of chronic pain co-morbid with Alzheimer's disease (AD), highlighting the prevalence of chronic pain among AD patients, the limitations of current treatments, and the need for further research and future directions.
Elsevier,
Autonomic Neuroscience: Basic and Clinical, Volume 240, July 2022
This review examines the role of the autonomic nervous system in controlling cerebral blood flow (CBF) in dementia, highlighting that while cerebral autoregulation remains largely intact, the loss of neurovascular coupling may drive cognitive dysfunction, and exploring clinical and animal studies to identify potential biomarkers and therapeutic targets.
Elsevier,
Ageing Research Reviews, Volume 77, May 2022
As the number of Alzheimer's disease (AD) patients rises, causing significant suffering and socioeconomic burden, extensive research has been dedicated to understanding its elusive pathogenesis, focusing on amyloid cascade, tau protein, neuroinflammation, metal ions, and oxidative stress, with oxidative stress serving as a central factor that bridges these mechanisms; this review comprehensively expands on the roles of oxidative stress in AD, providing clear figures to enhance understanding.
Elsevier,
Behavioural Brain Research, Volume 471, 5 August 2024
This review discusses the impact of Apolipoprotein-E4 (ApoE4) on cognitive performance in targeted-replacement human ApoE knock-in mice, finding that ApoE4 mice exhibit significant cognitive deficits compared to ApoE3 mice in various cognitive tests, indicating an intrinsic vulnerability in ApoE4 mice that may be exacerbated in the context of neurodegenerative diseases.
Elsevier,
Neuroscience Letters, Volume 836, 27 July 2024
This article discusses the impact of methionine oxidation on clusterin function in Alzheimer's disease, highlighting the elevated levels of MetO-clusterin in human and mouse brains affected by the disease, and how this oxidation compromises clusterin's chaperone function, potentially exacerbating beta-amyloid toxicity in Alzheimer's pathology.
Elsevier,
Behavioural Brain Research, Volume 465, 8 May 2024
This article discusses age-related changes in species-typical behaviors, such as exploration and grooming, in female 5xFAD mouse model of Alzheimer's disease, suggesting that these behaviors may serve as valuable indicators for modeling the decline in activities of daily living observed in AD patients and assessing the efficacy of potential therapeutics.
Elsevier,
Behavioural Brain Research, Volume 463, 12 April 2024
This article discusses the potential therapeutic strategy of enhancing mitophagy through rapamycin treatment to alleviate cognitive impairment in Alzheimer's disease by improving mitochondrial dysfunction and neuronal loss, suggesting a novel mechanism for the neuroprotective effects of rapamycin in AD.
Elsevier,
Behavioural Brain Research, Volume 456, 5 January 2024
This article discusses the manifestation of apathy-like behaviors in Alzheimer's disease (AD) and frontotemporal dementia (FTD) mouse models through the assessment of nest-building behavior, highlighting differences in nesting proficiency and anhedonia between tau transgenic mice lines, suggesting apathy-like phenotypes in the context of neurodegenerative diseases.
Elsevier,
Neuroscience Letters, Volume 810, 27 July 2023
This article investigates the distribution and levels of tau and other neuronal proteins in the submandibular gland and frontal cortex of individuals at different clinicopathological stages of Alzheimer's disease (AD), revealing differential protein levels and the presence of unique tau species in peripheral tissues, providing insights into the relationship between peripheral tissues and AD progression.
Elsevier,
Neuroscience Letters, Volume 803, 23 April 2023
This article investigates the potential therapeutic effects of glutamic-oxaloacetic transaminase (GOT) in Alzheimer's disease (AD) by reducing glutamate concentrations in the hippocampi of mice, leading to improved neurological function, reduced β-amyloid protein levels, enhanced cognitive performance, increased neuron count and synaptic density, and altered protein expression, suggesting a promising treatment approach for early-stage AD.
Elsevier,
Frontiers in Neuroendocrinology, Volume 69, April 2023
This review explores the potential therapeutic applications of the orexin system, focusing on its role as a target for treating various pathological conditions, including psychiatric and neurodegenerative diseases, and highlights the development of suvorexant as an orexin agent approved for insomnia treatment.
Elsevier,
Behavioural Brain Research, Volume 438, 13 February 2023
This article discusses the impact of early life sensorial intervention on behavioral patterns, peripheral immune-endocrine organs, corticosterone levels, and responses to NMDA-induced motor depression in male and female 3xTg-AD mice, highlighting sex and genotype differences in susceptibility to glutamatergic excitotoxicity and modulation of the neuroimmunoendocrine system in Alzheimer's disease.
Elsevier,
Behavioural Brain Research, Volume 437, 2 February 2023
This case report discusses the comparison of circulating levels of vascular endothelial growth factor (VEGF) and platelets between Alzheimer's disease (AD) patients and healthy older adults, revealing lower VEGF levels and a trend towards reduced platelet numbers in AD patients, indicating potential modifications in angiogenic factors associated with the disease.
Elsevier,
Advances in Nutrition, Volume 15, August 2024
Dementia is a global leading cause of disability and death among older adults, and there is a need to carefully evaluate existing evidence on related risk factors to guide future research. This review summarized and evaluated the most updated evidence on associations of various magnesium forms (supplements, dietary intake, and biomarkers) with cognitive outcomes in adults, based on evidence from randomized controlled trials and cohort studies.
Elsevier,
Archives of Gerontology and Geriatrics, Volume 123, August 2024
Olfactory impairments are notably present in MCI, particularly with significant declines in odor identification, similar to the primary sensory deficit observed in AD, suggesting the incorporation of odor identification tests for early AD detection.
Elsevier,
Archives of Gerontology and Geriatrics, Volume 123, August 2024
Interaction of human and socially assistive robot can have applicability in actual settings, and adoption to function in human environment for Alzheimer's disease. This review revealed that there are still several technical challenges that must be addressed in future advancements before being integrated in real life of individuals with Alzheimer's disease. The results will help move towards the establishment of best practices for the development of human and socially assistive robot interaction for Alzheimer's disease and, in turn, help enhance the experience of people suffering from this disease.
Elsevier,
Journal of Nutrition, Volume 154, July 2024
This study aimed to examine relationships among eating frequency, timing and time window, and cognitive performance and novel Alzheimer disease (AD) biomarkers in cognitively healthy and mildly cognitively impaired middle-aged and older adults. It concluded that an eating pattern characterized by less frequent eating and/or by earlier times is present in individuals with worse cognitive performance. The results shed light on the relevance of temporal eating patterns as potential early markers of behavioral or metabolic changes related to AD pathology.
Elsevier,
Archives of Medical Research, Volume 55, July 2024
This article provides evidence that disruption of the intestinal mucosal barrier contributes to sarcopenia and functional dependence in patients with AD. RE may be an effective therapy to strengthen the intestinal mucosal barrier, reduce sarcopenia, and improve functional performance in patients with AD.
Elsevier,
Heliyon, Volume 10, 30 April 2024
The study emphasizes practical application with a user-friendly website, empowering radiologists to predict class probabilities, track disease progression, and visualize patient images in both 2D and 3D formats, contributing significantly to the advancement of early AD detection.
Immunity, Volume 57, 9 April 2024
The activation of the innate immune system and subsequent neuroinflammation are common hallmarks of all neurodegenerative diseases. Castro-Gomez and Heneka review the emerging evidence related to receptors implicated in the activation of innate immunity during neurodegenerative processes. They predominantly focus on the role of microglia, PRRs, and other DAMP-sensing receptors in the pathogenesis of Alzheimer’s disease, tauopathy, Parkinson’s disease, and amyotrophic lateral sclerosis.
Elsevier,
Advances in Nutrition, Volume 15, April 2024
This perspective provides a pioneering synthesis of clinical intervention trials examining the effects of fasting and caloric restriction on individuals suffering from neurodegenerative diseases, marking a comprehensive analysis on this topic.
Elsevier,
International Journal of Clinical and Health Psychology, Volume 24, 1 April 2024
This article shows that rTMS over frontal regions and tDCS over temporal regions can improve memory abilities in people with Alzheimer's Disease. However, the prolonged effect of rTMS showed a statistical tendency towards enhancing memory, whereas the long-term effects of tDCS could not be assessed due to insufficient data.
Elsevier,
American Journal of Clinical Nutrition, Volume 119, April 2024
This study aimed to assess the associations of both serum vitamin D status and supplementation with all-cause dementia, Alzheimer’s disease (AD), and vascular dementia (VD) incidence. It highlighted consistent associations between various facets of vitamin D and multivitamin intake, objectively measured vitamin D deficiency and insufficiency from blood samples, and 14-year dementia incidence in a study population aged 55 to 69 years at baseline. Subgroup analyses revealed effect modification by skin color with associations only observed in the non-brown/non-black skin color group and stronger effect estimates for vitamin D supplementation in younger compared to older study participants. Although results are encouraging and suggest a potential role for vitamin D supplementation in dementia prevention, particularly for those with vitamin D deficiency, caution is advised due to the observational nature of this study. RCTs with long follow-up periods are indispensable to establishing the efficacy of dementia prevention strategies.
Elsevier,
Advances in Nutrition, Volume 15, March 2024
In the field of nutrition and brain aging research, dietary patterns, particularly the MIND diet, are a prominent area of interest. This systematic review provides an overview of studies examining the MIND diet in relation to brain aging. It updates previous systematic reviews with respect to cognition, cognitive decline, and dementia and extends to other brain aging outcomes including Parkinson’s disease, brain volume, and pathology.
Neurobiology of Stress, Volume 29, March 2024
This article discusses the association between stress exposure, alcohol consumption, and Alzheimer's Disease and related dementias (ADRD), emphasizing the importance of understanding behaviors that impact neurodegeneration and cognitive decline, and the need for preclinical research to uncover the underlying biological mechanisms.
Elsevier,
Revista Espanola de Geriatria y Gerontologia, Volume 59, 1 January 2024
The objective of this study was to assess the neuropsychological characteristics of individuals with early-onset Alzheimer's disease (EOAD), late-onset Alzheimer's disease (LOAD), and very-late-onset Alzheimer's disease (VLOAD). The findings indicate notable neuropsychological variations across different age groups, demonstrating a progressive decline in cognitive function with age rather than distinct clinical presentations.
Elsevier,
Current Developments in Nutrition, Volume 7, November 2023
This paper concludes that it is imperative to identify effective, early treatments for Alzheimer's disease. Creatine is an important bioenergetic molecule, and the Creatine system is shown to be dysfunctional in the brain of individuals with Alzheimer's disease. Therefore, Ceatine may serve as a potential target for prevention and therapy and creatine monohydrate supplementation may be beneficial in Alzheimer's disease. To date, only rodent studies have investigated the use of creatine monohydrate as a treatment for Alzheimer's disease.. Thus, clinical trials investigating the effects of creatine monohydrateon cognition and creatine monohydrate’s mechanisms in humans with Alzheimer's disease as well as its potential as a strategy to prevent cognitive decline in those with normal cognition, are needed. There is much to be learned about CrM intervention and brain health in different life and disease phases.
Elsevier,
The Lancet Regional Health - Western Pacific, Volume 39, October 2023
This article supports SDG 3 by assessing the changes in mortality rate and years of life lost associated with dementia attributable to high BMI in China. The findings suggest a rapid increase in dementia burden attributable to high BMI.
Elsevier,
Immunity, Volume 56, 12 September 2023
PLCγ2 is genetically linked to Alzheimer’s disease (AD), but it is unclear how PLCγ2 contributes to pathology. Tsai et al. demonstrate that AD-associated PLCG2 variants bidirectionally orchestrate microglial responses to plaques and impact neural function in an AD mouse model. This positions PLCγ2 as a key microglial signaling node and shows that targeting PLCγ2 could have therapeutic benefits in AD.
Elsevier,
Advances in Nutrition, Volume 14, July 2023
This review integrates the current evidence and potential mechanisms of gut microbiota and its metabolites in Alzheimer’s disease and comprehensively reviews the possibility of leveraging dietary interventions to prevent Alzheimer’s disease progression, with a focus on the gut–microbiota–brain connections and diet–metabolite–host interactions.
Elsevier,
American Journal of Clinical Nutrition, Volume 117, June 2023
This paper concludes that findings suggest that 1) long-term omega-3 fatty acid supplementation may reduce risk of Alzheimer’s disease (AD); 2) dietary omega-3 fatty acid intake, especially DHA, may lower risk of dementia or cognitive decline; and 3) peripheral biomarkers of omega-3 fatty acids may serve as predictors of cognitive decline. However, further investigation is needed to understand the gene–environment interactions involved in the intake of omega-3 fatty acids.
Elsevier,
Journal of Nutrition, Volume 153, May 2023
Alzheimer disease (AD) is a neurodegenerative condition defined by the build-up of amyloid plaques in the brain and intraneuronal tangles of the protein tau. Autophagy is a cellular cleaning process involved in the degradation of proteins, including proteins directly responsible for amyloid plaques, but its activity is compromised in AD. This study showed that reducing dietary protein intake can reduce mTORC1 activity and amyloid plaque deposition in the brains of male mice with a less aggressive model of Alzheimer's disease, but not in a more aggressive model or in female mice.
Elsevier, Heliyon, Volume 9, April 2023
This study was designed to explore the relationship between Alzheimer's disease (AD) rates and socioeconomic conditions in 120 countries. We used mixed effect models to investigate the relationship between the rates of AD and socioeconomic data. This study is among the first studies to put forward statistical evidence of a significant association between AD and other dementias among the elderly and socioeconomic inequality. These findings could help to inform the policies to be designed to improve the quality of interventions for AD.
Elsevier,
American Journal of Clinical Nutrition, Volume 117, March 2023
The paper proposes that Alzheimer's disease may be the consequence of a maladaptation to an evolutionary-based survival pathway triggered by fructose metabolism, which initially helps preserve critical brain functioning during starvation but becomes injurious when engaged for extensive periods. Although more studies are needed on the role of fructose metabolism and its metabolite, uric acid, in Alzheimer’s disease, it is suggested that both dietary and pharmacologic trials to reduce fructose exposure or block fructose metabolism should be performed to determine whether there is potential benefit in the prevention, management, or treatment of this disease.
Elsevier,
American Journal of Clinical Nutrition, Volume 116, December 2022
This study examined the cross-sectional and retrospective longitudinal associations between erythrocyte omege 3 (ω-3) index and cognition, brain imaging, and biomarkers among older adults. Longitudinally, low ω-3 index was associated with greater Aβ accumulation and WMS cognitive decline but unexpectedly with lower total Alzheimer’s Disease Assessment Scale cognitive subscale (ADAS-Cog) cognitive decline. Although no associations were cross-sectionally found in the whole population, low ω-3 index was associated with lower WMS cognition and higher tau accumulation among ApoE ε4 carriers.
Elsevier,
American Journal of Clinical Nutrition, Volume 116, 1 November 2022
The positive association of choline for cognition has been reported in both animal and human studies, yet the associations of choline with the risks of incident dementia or Alzheimer’s disease (AD) in humans is unclear and the objective of this paper was to test the hypothesis that lower or higher dietary choline intake is associated with increased or decreased, respectively, risks of incident dementia and AD. The paper concludes that low dietary choline intake was associated with increased risks of incident dementia and AD and that further investigations regarding the effects of high choline intake on dementia and AD risks are warranted.
Elsevier,
Advances in Nutrition, Volume 13, 1 March 2022
Factors that influence the risk of neurocognitive decline and Alzheimer's disease (AD) may provide insight into therapies for both disease treatment and prevention. Although age is the most striking risk factor for AD, it is notable that the prevalence of AD is higher in women, representing two-thirds of case. The role of estrogen replacement therapy in reducing the risk of cognitive decline as well as dementia-related morbidity and mortality remains an active area of research. This perspective presents a testable working model of estrogen's relation to cognition with novel effect modifiers, including the degree of cholinergic dysfunction and the availability of choline from endogenous and exogenous sources. It also shows novel routes of investigation related to estrogen replacement and its interactions with menopausal timing, cholinergic signaling, and the influence of the endogenous (i.e., common PEMT variants) and exogenous (i.e., dietary) choline supply on cognitive function and risk of age-related cognitive decline and dementia.
Elsevier,
Journal of Nutrition, Volume 152, 1 January 2022
There is growing evidence of strong associations between the pathogenesis of Alzheimer's disease (AD) and dysbiotic oral and gut microbiota. Recent studies demonstrated that isoorientin (ISO) is anti-inflammatory and alleviates markers of AD, which were hypothesized to be mediated by the oral and gut microbiota. This paper studied the effects of oral administration of ISO on AD-related markers and the oral and gut microbiota in mice and concluded that the microbiota-gut-brain axis is a potential mechanism by which ISO reduces AD-related markers in amyloid precursor protein/presenilin-1 mice mice.
Neurochemistry International, Volume 177, July 2024
This review provides a comprehensive overview of both conventional and novel therapeutic strategies for Alzheimer's disease (AD), highlighting traditional Acetylcholinesterase (AChE) inhibition and emerging approaches such as Butyrylcholinesterase (BChE) inhibition, Tau Protein inhibitors, and COX-2 inhibition, while also exploring the roles of endocannabinoids, cholesterol-lowering drugs, and microRNA, alongside novel research tools and current clinical trials, to offer a consolidated resource for advancing AD treatment and research.
Experimental Neurology, Volume 374, April 2024
This review explores the role of platelet dysfunction in the pathogenesis of Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA), discussing in vitro, in vivo, and clinical evidence related to platelet activation, adhesion, and aggregation, and highlighting potential therapeutic targets to address amyloid-related AD pathogenesis.
Acta Pharmaceutica Sinica B, 2024, ISSN 2211-3835
The study introduces a nano-modulator that targets the damaged blood-brain barrier in Alzheimer’s disease. This modulator releases therapeutic agents that reduce amyloid-beta load, alleviate neuroinflammation, and restore neurovascular unit function, showing potential for Alzheimer’s treatment.
Journal of Pharmaceutical Analysis, 2024, 101022, ISSN 2095-1779
This study developed four deep learning models to identify potential Alzheimer's disease treatments from traditional Chinese medicine, specifically the Kaixinsan formula. The models successfully predicted compounds that showed significant anti-Alzheimer's activities in various experimental validations.
Elsevier,
The American Journal of Medicine, Available online 27 August 2024
The present mini-commentary on Alzheimer's disease describes recently revealed pathogenic elements, evolving capabilities for identifying unusually high individual susceptibility and developing tests that predict onset preclinically to allow preventative approaches. Several potential therapies that target cellular signaling and other pathways that are abnormal in Alzheimer's disease are in early clinical trials and will be reviewed briefly.
Elsevier, A Review on Diverse Neurological Disorders: Pathophysiology, Molecular Mechanisms, and Therapeutics, Volume , 1 January 2024
Due to the aging population, both Alzheimer's disease (AD) and Parkinson's disease (PD) are degenerative brain disorders that are now recognized as important public health issues.
Elsevier, Microbial Biofilms: Role in Human Infectious Diseases, Volume , 1 January 2024
Humans harbor complex communities of microbes, predominantly bacteria, that live symbiotically within the colon. There are several factors that influence the trajectory of gut microbiota in infants such as birth term, mode of delivery, and dietary habits.
Elsevier, International Review of Neurobiology, Volume 177, January 2024
Alzheimer's disease (AD) stands as the most prevalent form of neuropsychiatric disorder among the elderly population, impacting a minimum of 50 million individuals worldwide. Current pharmacological treatments rely on the prescribing cholinesterase inhibitors and memantine.
Elsevier, Progress in Brain Research, Volume 289, January 2024
Coffee, a universally consumed beverage, is known to contain thousands of bioactive constituents that have garnered interest due to their potential neuroprotective effects against various neurodegenerative disorders, including Alzheimer's disease (AD).
Elsevier, Studies in Natural Products Chemistry, Volume 81, January 2024
Dementia is a progressive neurological and degenerative syndrome that affects an individuals' memory, thinking, and social abilities severely enough to interfere with their daily lives. It is emerging as a public health priority in terms of the associated disability and mortality.
Elsevier, Alzheimer's Disease and Advanced Drug Delivery Strategies, Volume , 1 January 2023
Alzheimer's disease (AD) is a severe global public health issue because it is an irreversible neurodegeneration of the brain that impairs personality, cognition, memory, and other functions before it ultimately results in death from total brain failure.
Elsevier, Side Effects of Drugs Annual, Volume 45, January 2023
Medications used in the treatment of Alzheimer's disease include the acetylcholinesterase inhibitors (AChEIs, i.e., donepezil, rivastigmine, and galantamine), the N-methyl-D-aspartate receptor (NDMAR) antagonist, memantine, and the anti-amyloid beta monoclonal antibody, aducanumab.
Elsevier, Diet and Nutrition in Neurological Disorders, Volume , 1 January 2023
This chapter discusses any plausible correlation between malnutrition and the onset of Alzheimer's disease. An overview of Alzheimer's pathophysiology is included to offer an understanding of the various underlying causes leading to its manifestation.
